This study is comparing standard of care treatments for patients with CRE (Carbapenem-Resistant Enterobacteriaceae). Eligible patients will be randomized 2:1 to either the investigational antibiotic Carbavance or standard of care. Carbavance is a combination medication consisting of meropenem (an approved antibiotic) and RPX7009. Patients will be treated up to 14 days and followed up to 2 weeks after treatment completion.
Who may be Eligible
Adults patients with know CRE infection; not pregnant or breastfeeding; agree to not become pregnant or father a child up to 30 days after study medication; agree to protocol defined birth control; normal maintenance labs as defined by protocol; not allergic to study medications; no co-morbid condition that will interfere with the study as defined by protocol; life expectancy greater than 72 hours; know or suspected endocarditis, meningitis, or osteomyelitis;